A subsequent analysis from these same PsA studies, which focused on spondylitis-related endpoints in tumor necrosis factor inhibitor (TNFi)-naïve patients with peripheral arthritis and physician reported-spondylitis, found that ustekinumab demonstrated clinically meaningful changes across BASDAI measures of neck/back/hip pain, as well as the modified BASDAI (omission of Question #3, peripheral joint pain or swelling), when compared with placebo. The gene discussed is TNF; the disease is spondylitis.